More than 200 research staff, students and industry professionals from across Australia are expected to attend the event. This event provides the opportunity for attendees to learn and share new techniques used in organoid research and network with others from various research institutions and companies.
The main themes covered this year will include fundamental organoid methodologies, cellular interactions, engineering models and precision medicine/clinical sessions. Our 2023 symposium program also welcomes presentations from Industry experts (Perkin Elmer and Tecan) who are designing and optimizing the next-generation tools supporting organoid research.
In 2022, the attendees declared that the symposium had a “Great selection of sessions and a fantastic opportunity to network at breaks” and “the event had a good balance covering both the basic methods and scientific knowledge of organoids”. 100% of them were looking forward to participating in the next Symposium.
Well, we are now less than 2 months away from this highly anticipated event!
Thanks to the generosity of the symposium sponsors: Biostrategy, Corning, Millennium Science, Perkin Elmer, Sartorius, StemCell Technologies and Tecan. The Monash Organoid Program is able to organise this symposium as a free, fully catered event. They will also provide attendees with barista-made coffees all day with the ‘Coffee on Cue’ coffee cart.
Stay tuned for the release of the official program in the coming weeks!
Phenomics Australia provides a national centre of expertise and service provision to deploy a more comprehensive and sophisticated range of in vitro Genome Engineering and Disease Modelling capabilities to understand the functional consequences of DNA sequence variation in the human genome for health and disease while maintaining the expertise for in vivo disease modelling and genome engineering. To meet the high demand for adaptable and scalable disease-modelling platforms for improved diagnosis, Precision Medicine for genetic disorders, and therapeutic development by both academia and the biopharmaceutical industry, Phenomics Australia offers In Vitro services through a collaborative consortium of ten laboratories and facilities across Australia, operating at ANU (ANU Centre for Therapeutic Discovery), Perkins (Translational Cancer Research Program in Oncology), Monash (Monash Organoid Program & Monash Genome Modification Platform), MCRI (iPSC derivation & Gene Editing Facility), Peter Mac (Victorian Centre for Functional Genomics), UMelb (Centre for Stem Cell Systems & Stem Cell Disease Modelling Laboratory), UQ (In vitro Genome Engineering and Disease Modelling Service), and VCCRI (Stem Cell Production Facility iPSC Reprogramming Service)